CD28 and neoplasm: This was also accompanied by the upregulation of proliferation marker MKI67, costimulatory genes (CD28, TNFRSF9 (4-1BB), and tumor-reactivity markers (e.g., ENTPD1/CD39, ITGAE/CD103) suggestive of an anti-tumor response in face of rising tumor levels (Fig. 6e).